» Articles » PMID: 26561643

Inflammation in AKI: Current Understanding, Key Questions, and Knowledge Gaps

Overview
Specialty Nephrology
Date 2015 Nov 13
PMID 26561643
Citations 279
Authors
Affiliations
Soon will be listed here.
Abstract

Inflammation is a complex biologic response that is essential for eliminating microbial pathogens and repairing tissue after injury. AKI associates with intrarenal and systemic inflammation; thus, improved understanding of the cellular and molecular mechanisms underlying the inflammatory response has high potential for identifying effective therapies to prevent or ameliorate AKI. In the past decade, much knowledge has been generated about the fundamental mechanisms of inflammation. Experimental work in small animal models has revealed many details of the inflammatory response that occurs within the kidney after typical causes of AKI, including insights into the molecular signals released by dying cells, the role of pattern recognition receptors, the diverse subtypes of resident and recruited immune cells, and the phased transition from destructive to reparative inflammation. Although this expansion of the basic knowledge base has increased the number of mechanistically relevant targets of intervention, progress in developing therapies that improve AKI outcomes by modulation of inflammation remains slow. In this article, we summarize the most important recent developments in understanding the inflammatory mechanisms of AKI, highlight key limitations of the commonly used animal models and clinical trial designs that may prevent successful clinical application, and suggest priority approaches for research toward clinical translation in this area.

Citing Articles

The Potential Role of Advanced Glycation End Products in the Development of Kidney Disease.

Ma Y, Wang X, Lin S, King L, Liu L Nutrients. 2025; 17(5).

PMID: 40077627 PMC: 11902189. DOI: 10.3390/nu17050758.


Transfusion Thresholds and Risk Factors of Acute Kidney Injury in Gastrointestinal Oncology Surgery: Insights from a Retrospective Study.

Ma S, He Q, Yang C, Zhou Z, He Y, Yu C Healthcare (Basel). 2025; 13(5).

PMID: 40077087 PMC: 11898515. DOI: 10.3390/healthcare13050525.


New drugs for acute kidney injury.

Hariri G, Legrand M J Intensive Med. 2025; 5(1):3-11.

PMID: 39872831 PMC: 11763585. DOI: 10.1016/j.jointm.2024.08.001.


Neutrophil heterogeneity and plasticity: unveiling the multifaceted roles in health and disease.

He W, Yan L, Hu D, Hao J, Liou Y, Luo G MedComm (2020). 2025; 6(2):e70063.

PMID: 39845896 PMC: 11751288. DOI: 10.1002/mco2.70063.


Kidney Injury Following Cardiac Surgery: A Review of Our Current Understanding.

Kamla C, Meersch-Dini M, Palma L Am J Cardiovasc Drugs. 2025; .

PMID: 39799538 DOI: 10.1007/s40256-024-00715-8.


References
1.
Kinasewitz G, Chang A, Peer G, Hinshaw L, Taylor Jr F . Peritonitis in the baboon: a primate model which stimulates human sepsis. Shock. 2000; 13(2):100-9. DOI: 10.1097/00024382-200013020-00003. View

2.
Bajwa A, Huang L, Ye H, Dondeti K, Song S, Rosin D . Dendritic cell sphingosine 1-phosphate receptor-3 regulates Th1-Th2 polarity in kidney ischemia-reperfusion injury. J Immunol. 2012; 189(5):2584-96. PMC: 3433235. DOI: 10.4049/jimmunol.1200999. View

3.
Kinsey G, Li L, Okusa M . Inflammation in acute kidney injury. Nephron Exp Nephrol. 2008; 109(4):e102-7. PMC: 2614446. DOI: 10.1159/000142934. View

4.
Linfert D, Chowdhry T, Rabb H . Lymphocytes and ischemia-reperfusion injury. Transplant Rev (Orlando). 2008; 23(1):1-10. PMC: 2651229. DOI: 10.1016/j.trre.2008.08.003. View

5.
Nelson P, Rees A, Griffin M, Hughes J, Kurts C, Duffield J . The renal mononuclear phagocytic system. J Am Soc Nephrol. 2011; 23(2):194-203. PMC: 3269181. DOI: 10.1681/ASN.2011070680. View